摘要
背景:银杏叶提取物EGb761通过对Aβ诱导的神经毒性的保护显示对阿尔茨海默氏病(AD)的神经保护作用。然而,尚不完全清楚EGb761是否减弱了tau蛋白过度磷酸化,这是AD病理学的另一个最重要的机制。 方法:采用高同型半胱氨酸血症模型(HHcy)模拟大鼠模型的AD病理改变和记忆障碍,并注射EGb761或注射HHcy后预防和治疗,注射生理盐水作为对照。我们测量了老鼠的氧化损伤和空间和学习记忆的状态。然后通过Western blotting和免疫组织化学方法检测记忆相关蛋白水平,tau蛋白磷酸化水平和tau蛋白激酶(GSK-3β)和磷酸酶(PP2A)活性。 结果:我们发现EGb761可显着拮抗HHcy诱导的氧化损伤,恢复HHcy失调的PP2Ac和GSK3β活性。此外,在HHcy大鼠的海马和前额叶皮质中,tau蛋白在Thr231,Ser262,Ser396和Ser404,最常见的PP2Ac和GSK3β靶向位点过度磷酸化,而EGb761在这些位点恢复了tau磷酸化。行为测试表明,EGb761拯救了HHcy诱导的空间参考记忆缺陷,并上调了突触相关蛋白PSD95和突触蛋白-1的表达。 结论:除抗Aβ诱导的神经毒性外,EGb761可能通过其抗氧化活性和降低tau蛋白过度磷酸化而成为治疗AD的有效药物。
关键词: 银杏提取物EGb761,阿尔茨海默病(AD),高同型半胱氨酸血症(HHcy),tau过度磷酸化,认知障碍,氧化损伤。
Current Alzheimer Research
Title:Ginkgo biloba Extract EGb761 Attenuates Hyperhomocysteinemia-induced AD Like Tau Hyperphosphorylation and Cognitive Impairment in Rats
Volume: 15 Issue: 1
关键词: 银杏提取物EGb761,阿尔茨海默病(AD),高同型半胱氨酸血症(HHcy),tau过度磷酸化,认知障碍,氧化损伤。
摘要: Background: Ginkgo biloba extract EGb761 has shown the neuroprotective effects on Alzheimer's disease (AD) through the protection against the Aβ-induced neurotoxicity. However, it is not completedly clear whether EGb761 attenuates tau hyperphosphorylation, another of the most prominent mechanisms underlying the pathology of AD.
Methods: we employed hyperhomocysteinemia (HHcy) to mimic AD like pathological alterations and memory deficits in rats as model, and injected EGb761 with or after HHcy injection as prevention and treatment, injected saline as control. We measured the status of oxidative damage and spatial and learning memory in rats. Then we detected the level of memory-related proteins, tau phosphorylation and the level and activity of tau kinase (GSK-3β) and phosphatase (PP2A) by Western blotting and Immunohistochemistry.
Results: We found that EGb761 could significantly antagonize HHcy-induced oxidative damage, recover PP2Ac and GSK3β activities deregulated by HHcy. Furthermore, tau was hyperphosphorylated at Thr231, Ser262, Ser396, and Ser404, most common PP2Ac and GSK3β targeted sites in the hippocampus and prefrontal cortex of HHcy rats, whereas EGb761 recovered the tau phosphorylation at those sites. Behavioral tests revealed that EGb761 rescued HHcy-induced spatial reference memory deficit and upregulated the expression of synapse-associated protein PSD95 and synapsin-1.
Conclusion: EGb761 might be a promising drug to treat AD through its anti-oxidative activity and decreasing tau hyperphosphorylation besides the protection against the Aβ-induced neurotoxicity.
Export Options
About this article
Cite this article as:
Ginkgo biloba Extract EGb761 Attenuates Hyperhomocysteinemia-induced AD Like Tau Hyperphosphorylation and Cognitive Impairment in Rats, Current Alzheimer Research 2018; 15 (1) . https://dx.doi.org/10.2174/1567205014666170829102135
DOI https://dx.doi.org/10.2174/1567205014666170829102135 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New Preparative Approaches for Micro and Nano Drug Delivery Carriers
Current Drug Delivery Individualized Treatment Planning in Oncology: Role of PET and Radiolabelled Anticancer Drugs in Predicting Tumour Resistance
Current Pharmaceutical Design Targeting ATP7A to Increase the Sensitivity of Neuroblastoma Cells to Retinoid Therapy
Current Cancer Drug Targets Therapy in Prion Diseases: From Molecular and Cellular Biology to Therapeutic Targets
Infectious Disorders - Drug Targets Developing Histone Deacetylase Inhibitors as Anti-Cancer Therapeutics
Current Medicinal Chemistry CDC25A: A Rebel Within the CDC25 Phosphatases Family?
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in Radiation Therapy of Cancer Cells: A Step towards an Experimental and Systems Biology Framework
Current Radiopharmaceuticals Identification and Targeting of Tumor Escape Mechanisms: A New Hope for Cancer Therapy?
Current Pharmaceutical Design MicroRNA-dependent Regulation of Telomere Maintenance Mechanisms: A Field as Much Unexplored as Potentially Promising
Current Pharmaceutical Design Role of Catechol-O-Methyltransferase (COMT)-Dependent Processes in Parkinson’s Disease and L-DOPA Treatment
CNS & Neurological Disorders - Drug Targets Targeting Ovarian Cancer-Initiating Cells
Anti-Cancer Agents in Medicinal Chemistry Viral and Non-Viral Approaches for Transient Delivery of mRNA and Proteins
Current Gene Therapy The Heat Shock Protein 90 Chaperone Complex: An Evolving Therapeutic Target
Current Cancer Drug Targets Chemoprotective and Carcinogenic Effects of tert-Butylhydroquinone and Its Metabolites
Current Drug Metabolism Improving the Targeting of Tubulin-Binding Agents: Lessons from Drug Resistance Studies
Current Pharmaceutical Design Neurokinin-1 Receptor Antagonists in Lung Cancer Therapy
Letters in Drug Design & Discovery Genetically Modified Dendritic Cells for Cancer Immunotherapy
Current Gene Therapy TRP Channels: New Potential Therapeutic Approaches in CNS Neuropathies
CNS & Neurological Disorders - Drug Targets Cell Surface Nucleolin as a Target for Anti-Cancer Therapies
Recent Patents on Anti-Cancer Drug Discovery Targeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet?
Current Medicinal Chemistry